Evidence map›Paper›PMID 41874779›Full record

ArticleDigestive diseases and sciences2026

Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease.

Andrew R Roney, Dupre Orr, Armeen Barghi, Sureya Hussani, Vivy Cusumano, Berkeley N Limketkai, Jenny S Sauk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew R RoneyDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Dupre OrrDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Armeen BarghiDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sureya HussaniDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Vivy CusumanoDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Berkeley N LimketkaiDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jenny S SaukDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA. jsauk@mednet.ucla.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeShort- and medium-term safety profiles of anti-TNF therapies are well-established, but data on their long-term safety, especially beyond five years, remain limited. This study aims to compare the risk of adverse events (AEs) in patients on stable anti-TNF therapy for less than five years versus more than five years.

methodsA retrospective cohort study was conducted in an outpatient IBD clinic from April 2015 to November 2023. Patients were divided into short-term (less than five years) and long-term (more than five years) therapy groups. AEs were tracked across multiple systems, and time-adjusted risks were compared using multivariable Cox proportional hazards models.

resultsWe identified 640 patients (785 instances) receiving stable anti-TNF therapy. A total of 82 AEs were reported over 1774 person-years. The AE incidence per 100 person-years was 5.12 in the short-term group and 3.50 in the long-term group with no significant adjusted risk between groups (aHR, 0.62; 95% CI 0.35 to 1.11). However, patients with CD on long-term infliximab therapy signaled a lower risk of AEs compared to short-term users (aHR, 0.33; 95% CI 0.11 to 1.00). Dermatologic events were the most common AEs.

conclusionLong-term anti-TNF therapy appears to have a similar safety profile to short-term therapy, with no significant increase in overall AE risk. These findings may offer cautious reassurance regarding extended anti-TNF use, particularly in patients with CD on infliximab.

Indexed as

Gastrointestinal AgentsInflammatory Bowel DiseasesInfliximabTumor Necrosis Factor-alphaAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeGastrointestinal AgentsInfliximabTumor Necrosis Factor-alphaAdverse eventsAnti-tumor necrosis factorInflammatory bowel diseaseLong-termSafety

Identifiers

PMID41874779
PMCPMC13500413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.